Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was declared a global pandemic in March 2020 by the WHO. During the time since it emerged into a global crisis, there have been several recommendations to prevent spread of infection and to manage COVID-19 infected patients through supportive care, plasma therapy, oxygen support, and support of other affected vital organs.

Treatment options for COVID-19 are now emerging through several global clinical trials on antivirals, and the Indian Medical Association (Maharasthra) welcomes you to a live webinar to understand the use of antiviral Favipiravir in treatment of COVID-19 patients. During this webinar supported by Glenmark Pharmaceuticals, phase 3 clinical trial (CT) outcomes with Flavipiravir will be presented for the information of health care professionals.  

The key points discussed during webinar will be as follows:

Antivirals in COVID-19

• Why treatment with antiviral is a key?
• Timing of antiviral treatment-  Hit Early, Hit Hard

Favipiravir Snapshot

• Molecule Profile
• Current Global Status

Indian RCT – Topline Results

• Study design
• Efficacy Outcomes
• Safety Outcomes